• About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Human Metapneumovirus
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
    • Out-Licensing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Governance
    • Investor Resources
  • Contact Us

EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC suppressed CHB Patients

EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients

EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist: Results of a Phase 1 Study in Healthy Subjects

Pharmacological Inhibition of HSD17B13 Is Hepatoprotective In Mouse Models of Liver Injury

Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor

Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge

Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease

EDP-514, a Novel Pangeonotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in NUC-Suppressed CHB Patients

EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients

enanta logo

©2022 Enanta Pharmaceuticals, Inc.

ENANTA PHARMACEUTICALS and accompanying logos are trademarks or registered trademarks of Enanta Pharmaceuticals, Inc.

Explore

  • About
  • Pipeline
  • Science
  • Patients
  • Careers
  • Collaborations
  • Investors
  • Contact Us

Contact

Enanta Pharmaceuticals, Inc.
Headquarters
500 Arsenal Street
Watertown, MA 02472

(617) 607-0800
info@enanta.com

Legal

  • Privacy Policy
  • Twitter Policy
  • Terms of Use
social media icon social media icon
MENU
  • About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Human Metapneumovirus
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
    • Out-Licensing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Governance
    • Investor Resources
  • Contact Us